SCHEDULE: Morgan Stanley Reduces Jasper Therapeutics Stake Below 5%

Morgan Stanley has filed an amended Schedule 13G, indicating it no longer beneficially owns more than five percent of Jasper Therapeutics, Inc.'s voting common stock.

Summary

• Morgan Stanley filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Jasper Therapeutics, Inc. (CUSIP: 471871202).
• The filing states that Morgan Stanley has ceased to be the beneficial owner of more than five percent of Jasper Therapeutics' voting common stock.
• As of the event date of September 30, 2025, Morgan Stanley beneficially owned 784,628 shares, representing 2.8% of the class.
• Morgan Stanley holds shared voting power over 784,428 shares and shared dispositive power over 784,628 shares.

Sentiment

Score: 3

Explanation: The filing indicates a major institutional investor, Morgan Stanley, has reduced its stake below the 5% threshold, which is generally viewed as a negative signal for the issuer, Jasper Therapeutics, as it suggests reduced institutional confidence or a strategic divestment.

Negatives

• Morgan Stanley, a significant institutional investor, has reduced its beneficial ownership in Jasper Therapeutics, Inc. below the 5% threshold.
• This reduction could be interpreted by the market as a decrease in institutional confidence or a portfolio rebalancing away from the issuer.

Future Outlook

NA

Industry Context

This filing reflects a routine portfolio adjustment by a major financial institution, Morgan Stanley, regarding its stake in a biotechnology or pharmaceutical company, Jasper Therapeutics. Such adjustments are common and can be driven by various factors including investment strategy shifts, risk management, or changes in the institution's outlook on the specific company or sector.

Stakeholder Impact

• Shareholders: Existing shareholders might perceive the reduction in Morgan Stanley's stake as a negative signal, potentially leading to downward pressure on the stock price.
• Potential Investors: New investors might be more cautious given the divestment by a major institution.

Key Dates

Recommendation

The reduction of a significant institutional stake by Morgan Stanley below the 5% threshold typically signals a lack of conviction or a strategic divestment. This could lead to negative market sentiment and potential downward pressure on Jasper Therapeutics' stock price, suggesting a 'sell' recommendation for investors looking to avoid potential losses or reallocate capital.

Keywords

Jasper Therapeutics, Morgan Stanley, Schedule 13G, Beneficial Ownership, Stock Ownership, Institutional Investor, Voting Common Stock, SEC Filing, Equity Stake